Evidence map›Paper›PMID 41360672›Full record

ReviewCancer medicine2025

Advances in Tumor-Derived Exosomal Non-Coding RNAs Regulating M2 Macrophage Polarization: Molecular Mechanisms and Signaling Pathway.

Yifan Bian, Jilei Li, Jiarui Cao, Sizhe Wang, Chunzheng Ma

Abstract readReview
In one paragraph

Review in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yifan BianHenan University of Chinese Medicine, Zhengzhou, Henan, China.ORCID https://orcid.org/0009-0002-4102-4861
Jilei LiHenan Province Hospital of TCM, Zhengzhou, Henan, China.ORCID https://orcid.org/0000-0003-0783-4449
Jiarui CaoHenan University of Chinese Medicine, Zhengzhou, Henan, China.ORCID https://orcid.org/0009-0005-4073-0344
Sizhe WangHenan University of Chinese Medicine, Zhengzhou, Henan, China.ORCID https://orcid.org/0009-0007-6519-460X
Chunzheng MaHenan Province Hospital of TCM, Zhengzhou, Henan, China.ORCID https://orcid.org/0009-0007-9801-293X

Funding

Henan Province Administration of Traditional Chinese Medicine 2022ZY1089Henan Province Administration of Traditional Chinese Medicine 2024ZY1013Henan Provincial Hospital of Traditional Chinese Medicine Doctoral Fund 2024BSJJ10Leading Talents of Henan Province (2021)-8
6 · The paper itself

Abstract

backgroundCancer persists as a leading cause of global mortality, largely due to the immunosuppressive tumor microenvironment (TME) that facilitates tumor progression and therapy resistance. M2 macrophages dominate this immunosuppressive landscape, and emerging evidence highlights tumor-derived exosomes (TEXs) as critical mediators of macrophage M2 polarization via delivery of noncoding RNAs (ncRNAs), including miRNAs, lncRNAs, and circRNAs. These TEX-ncRNA networks activate key signaling pathways (e.g., JAK/STAT, PI3K/AKT, NF-κB) to sustain immunosuppression and pro-tumorigenic responses. Understanding the molecular intricacies of TEX-driven M2 polarization is essential for advancing immunotherapeutic strategies.

methodsThis review systematically analyzes literature (2019-2024, from PubMed and Web of Science) on the molecular mechanisms by which TEX-derived ncRNAs drive M2 polarization and their interplay with immunotherapies. RESULTS AND

conclusionThis review contains 142 citations, 60 of which are detailed examples of this mechanism. Our analysis of the literature shows that TEXs deliver specific ncRNAs to macrophages, reprogramming them toward an M2 phenotype via pathways such as PTEN/PI3Kγ, Wnt/β-catenin, and STAT3. This polarization amplifies immunosuppressive factor secretion and promotes tumor metastasis, chemoresistance, and immune evasion. These insights provide a theoretical foundation for novel TME-targeted therapies, potentially improving outcomes in refractory cancers.

Indexed as

ExosomesMacrophagesNeoplasmsRNA, UntranslatedAnimalsHumansMacrophage ActivationRNA, Long NoncodingSignal TransductionTumor-Associated MacrophagesTumor MicroenvironmentRNA, Long NoncodingRNA, Untranslatedexosomesimmune cellsimmunosuppressive tumor microenvironmentimmunotherapy resistanceM2 macrophage polarizationnon‐coding RNA

Identifiers

PMID41360672
PMCPMC12685473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.